Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors

被引：66

作者：

Demirer, Taner ^{[1
]}

Barkholt, Lisbeth ^{[3
]}

Blaise, Didier ^{[11
]}

Pedrazzoli, Paolo ^{[4
]}

Aglietta, Massimo ^{[5
]}

Carella, Angelo Michele ^{[6
]}

Bay, Jacques-Olivier ^{[9
]}

Arpaci, Fikret ^{[2
]}

Rosti, Giovanni ^{[7
]}

Gurman, Gunhan ^{[1
]}

Niederwieser, Dietger ^{[10
]}

Bregni, Marco ^{[8
]}

机构：

[1] Ankara Univ, Sch Med, Dept Haematol Oncol, TR-06100 Ankara, Turkey

[2] Ankara Univ, Sch Med, Dept Med Oncol, TR-06100 Ankara, Turkey

[3] Karolinska Univ, Huddinge Hosp, Huddinge, Sweden

[4] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy

[5] Inst Canc Res & Treatment, Turin, Italy

[6] Azienda Osped Univ San Martino, Div Ematol, Genoa, Italy

[7] Osped Reg, Treviso, Italy

[8] Ist Sci San Raffaele, Dept Oncol, Strateg Program Oncol, I-20132 Milan, Italy

[9] Ctr Jean Perrin CHU Clermont Ferrand, Federat Greffe Moelle & Therapie Cellulaire Auver, Clermont Ferrand, France

[10] Univ Hosp Leipzig, Div Hematol Oncol, Leipzig, Germany

[11] Inst Paoli Calmettes, Marseille, France

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 05期

关键词：

allogeneic stem-cell transplantation; graft-versus-host; graft-versus-tumor; immunotherapy; renal cell carcinoma (RCC);

D O I：

10.1038/ncponc1104

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an immune graft-versus-tumor (GVT) effect mediated by donor lymphocytes. The development of nonmyeloablative conditioning regimens before allogeneic transplantation has allowed this therapy to be used in elderly and disabled patients. An allogeneic GVT effect is observed in a proportion of patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with allogeneic transplantation. In general, the tumor response is associated with the development of acute and chronic graft-versus-host disease. Further improvements will depend on the identification of the antigen targets of GVT, and on reduction of the toxicity of the procedure. Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party.

引用

页码：256 / 267

页数：12

共 86 条

[1] Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].

Aoudjhane, M ;

Labopin, M ;

Gorin, NC ;

Shimoni, A ;

Ruutu, T ;

Kolb, HJ ;

Frassoni, F ;

Boiron, JM ;

Yin, JL ;

Finke, J ;

Shouten, H ;

Blaise, D ;

Falda, M ;

Fauser, AA ;

Esteve, J ;

Polge, E ;

Slavin, S ;

Niederwieser, D ;

Nagler, A ;

Rocha, V .

LEUKEMIA, 2005, 19 (12) :2304-2312

[2] Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe [J].

Barkholt, L. ;

Bregni, M. ;

Remberger, M. ;

Blaise, D. ;

Peccatori, J. ;

Massenkeil, G. ;

Pedrazzoli, P. ;

Zambelli, A. ;

Bay, J. -O. ;

Francois, S. ;

Martino, R. ;

Bengala, C. ;

Brune, M. ;

Lenhoff, S. ;

Porcellini, A. ;

Falda, M. ;

Siena, S. ;

Demirer, T. ;

Niederwieser, D. ;

Ringden, O. .

ANNALS OF ONCOLOGY, 2006, 17 (07) :1134-1140

[3]

Baron F, 2003, HAEMATOLOGICA, V88, P478

[4] Ovarian cancer - Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients [J].

Bay, JO ;

Fleury, J ;

Choufi, B ;

Tournilhac, O ;

Vincent, C ;

Bailly, C ;

Dauplat, J ;

Viens, P ;

Faucher, C ;

Blaise, D .

BONE MARROW TRANSPLANTATION, 2002, 30 (02) :95-102

[5] Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer [J].

Bishop, MR ;

Fowler, DH ;

Marchigiani, D ;

Castro, K ;

Kasten-Sportes, C ;

Steinberg, SM ;

Gea-Banacloche, JC ;

Dean, R ;

Chow, CK ;

Carter, C ;

Read, EJ ;

Leitman, S ;

Gress, R .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3886-3892

[6] Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors [J].

Blaise, D ;

Bay, JO ;

Faucher, C ;

Michallet, M ;

Boiron, JM ;

Choufi, B ;

Cahn, JY ;

Gratecos, N ;

Sotto, JJ ;

François, S ;

Fleury, J ;

Mohty, M ;

Chabannon, C ;

Bilger, K ;

Gravis, G ;

Viret, F ;

Braud, AC ;

Bardou, VJ ;

Maraninchi, D ;

Viens, P .

BLOOD, 2004, 103 (02) :435-441

[7] Safety of retroviral gene marking with a truncated NGF receptor [J].

Bonini, C ;

Grez, M ;

Traversari, C ;

Ciceri, F ;

Marktel, S ;

Ferrari, G ;

Dinauer, M ;

Sadat, M ;

Aiuti, A ;

Deola, S ;

Radrizzani, M ;

Hagenbeek, A ;

Apperley, J ;

Ebeling, S ;

Martens, A ;

Kolb, HJ ;

Weber, M ;

Lotti, F ;

Grande, A ;

Weissinger, E ;

Bueren, JA ;

Lamana, M ;

Falkenburg, JHF ;

Heemskerk, MHM ;

Austin, T ;

Kornblau, S ;

Marini, F ;

Benati, C ;

Magnani, Z ;

Cazzaniga, S ;

Toma, S ;

Gallo-Stampino, C ;

Introna, M ;

Slavin, S ;

Greenberg, PD ;

Bregni, M ;

Mavilio, F ;

Bordignon, C .

NATURE MEDICINE, 2003, 9 (04) :367-369

[8] A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma [J].

Brandle, D ;

Brasseur, F ;

Weynants, P ;

Boon, T ;

VandenEynde, BJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2501-2508

[9] The Second International Meeting on Allogeneic Transplantation in Solid Tumors [J].

M Bregni ;

N T Ueno ;

R Childs .

Bone Marrow Transplantation, 2006, 38 (8) :527-537

[10]

Bregni M, 2003, BONE MARROW TRANSPL, V31, pS36

← 1 2 3 4 5 6 7 8 9 →